Preterm Labor Magnesium Sulfate Admission [1470]

General Admission Orders (Single Response) (Selection Required) Do not use Outpatient Observation Services Under General Supervision order for patients who are receiving Outpatient TRIAGE services. (X) Admit to L&D Admitting Physician: Diagnosis: Pregnancy Bed request comments: L&D Pre-Delivery **Code Status** [X] Full code Code Status decision reached by: Patient by means of Oral Directive [] DNR (Do Not Resuscitate) (Selection Required) Does patient have decision-making capacity? [] DNR (Do Not Resuscitate) L&D Pre-Delivery [] Consult to Palliative Care Service Priority: Reason for Consult? Order? Name of referring provider: Enter call back number: Consult to Social Work Reason for Consult: L&D Pre-Delivery [] Modified Code Does patient have decision-making capacity? Modified Code restrictions: L&D Pre-Delivery Treatment Restriction decision reached by: **Treatment Restrictions Specify Treatment Restrictions:** L&D Pre-Delivery Isolation [] Airborne isolation status [] Airborne isolation status Details [] Mycobacterium tuberculosis by PCR - If you Once, Sputum, L&D Pre-Delivery suspect Tuberculosis, please order this test for rapid diagnostics. [] Contact isolation status **Details** Details Droplet isolation status [] Enteric isolation status Details **Precautions** Aspiration precautions L&D Pre-Delivery [] Fall precautions Increased observation level needed: On Admission and every 8 hours, L&D Pre-Delivery Latex precautions L&D Pre-Delivery [] Seizure precautions Increased observation level needed: L&D Pre-Delivery **Common Present on Admission Diagnosis** [] Acidosis L&D Pre-Delivery [] Acute Post-Hemorrhagic Anemia L&D Pre-Delivery [] Acute Renal Failure L&D Pre-Delivery [] Acute Respiratory Failure L&D Pre-Delivery [] Acute Thromboembolism of Deep Veins of Lower L&D Pre-Delivery Extremities Anemia L&D Pre-Delivery

[] Bacteremia	L&D Pre-Delivery
[] Bipolar disorder, unspecified	L&D Pre-Delivery
[] Cardiac Arrest	L&D Pre-Delivery
[] Cardiac Dysrhythmia	L&D Pre-Delivery
[] Cardiogenic Shock	L&D Pre-Delivery
[] Decubitus Ulcer	L&D Pre-Delivery
[] Dementia in Conditions Classified Elsewhere	L&D Pre-Delivery
Disorder of Liver	L&D Pre-Delivery
[] Electrolyte and Fluid Disorder	L&D Pre-Delivery
[] Intestinal Infection due to Clostridium Difficile	L&D Pre-Delivery
[] Methicillin Resistant Staphylococcus Aureus Infection	L&D Pre-Delivery
[] Obstructive Chronic Bronchitis with Exacerbation	L&D Pre-Delivery
[] Other Alteration of Consciousness	L&D Pre-Delivery
[] Other and Unspecified Coagulation Defects	L&D Pre-Delivery
[] Other Pulmonary Embolism and Infarction	L&D Pre-Delivery
[] Phlebitis and Thrombophlebitis	L&D Pre-Delivery
[] Protein-calorie Malnutrition	L&D Pre-Delivery
[] Psychosis, unspecified psychosis type	L&D Pre-Delivery
[] Schizophrenia Disorder	L&D Pre-Delivery
[] Sepsis	L&D Pre-Delivery
[] Septic Shock	L&D Pre-Delivery
[] Septicemia	L&D Pre-Delivery
[] Type II or Unspecified Type Diabetes Mellitus with	L&D Pre-Delivery
Mention of Complication, Not Stated as Uncontrolled	•
[] Urinary Tract Infection, Site Not Specified	L&D Pre-Delivery
[] Present on Admission-History of preterm premature rupture of membranes	L&D Pre-Delivery
Nursing	
Vital Signs	
[X] Neuro checks	Routine, Until discontinued, Starting S
	Every 5 minutes during initiation of loading dose, then every
	15 minutes x 3, then every 30 minutes x 2, then every 1 hour,
	or as based on patient acuity/physician order. Notify physician
	for decrease or change in level of consciousness.
[X] Pulse oximetry	Routine, Every 2 hours
	Current FIO2 or Room Air:
	Monitor continuously throughout loading dose and then spot
	check every 2 hours while assessing maternal respiratory
	effort and breath sounds. Notify MD if SaO2 is less than 94%

L&D Pre-Delivery

Α.	Ο.	•	I٦		81	FW.	
-	١.		I١	•		ı w	,
-	_	•	- '	-	= ,	- 3	

[X] Vital signs - T/P/R/BP

[] Bacteremia

[] Strict bed rest	Routine, Until discontinued, Starting S
[X] Bed rest with bathroom privileges	Routine, Until discontinued, Starting S
	Bathroom Privileges: with bathroom privileges
[] Bed rest with bathroom privileges for BM only	Routine, Until discontinued, Starting S
	Bathroom Privileges: with bathroom privileges
	For bowel movement only

Routine, Every 5 min

Prior to administration of Magnesium Sulfate. Every 5 minutes during loading dose, then every 30 minutes until stable, then hourly 8 times then, if stable, every 4 hours.

Nursing Care

[X] Assess breath sounds	Routine, Every 2 hours Assess: breath sounds Maternal respiratory effort and breath sounds every 2 hours, or if stable, every four hours while awake per physician orders. Notify physician for shortness of breath or tightness in chest.
[X] Assess deep tendon reflex	Routine, Until discontinued, Starting S Prior to administration of Magnesium Sulfate: Every 5 minutes during loading dose, then every 30 minutes until stable, then hourly. Notify physician for decreased or absent deep tendon reflexes.
[X] Monitor fetal heart tones	Routine, Once Type: Continuous
[X] Tocometry	Routine, Until discontinued, Starting S Type: Continuous
[X] Strict intake and output	Routine, Every hour Hourly intake and output for the first 8 hours, then if patient is stable, every 4 hours.
[] Insert and maintain Foley	
[] Insert Foley catheter	Routine, Once Type: Size: Urinometer needed:
[] Foley Catheter Care	Routine, Until discontinued, Starting S Orders: Maintain
Consent	
[X] Complete Consent Form	Routine, Once Consent For: Delivery Procedure: Vaginal delivery of fetus and placenta with possible cesarean section, possible episiotomy, possible use of vacuum/forceps, and possible use of blood products. Diagnosis/Condition: Physician: L&D Pre-Delivery
Diet	
[] NPO	Diet effective now, Starting S NPO: Pre-Operative fasting options: L&D Pre-Delivery
[X] NPO with ice chips	Diet effective now, Starting S NPO: Except Ice chips Pre-Operative fasting options: 1/2 cup per hour, L&D Pre-Delivery
[] Diet - Clear liquids	Diet effective now, Starting S Diet(s): Clear Liquids Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: L&D Pre-Delivery
[] Diet - Regular Notify	Diet effective now, Starting S Diet(s): Regular Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid: L&D Pre-Delivery
Nothy	

Routine, Until discontinued, Starting S Temperature greater than: Temperature less than: Systolic BP greater than: Systolic BP less than: Diastolic BP greater than: Diastolic BP less than: MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94 Routine, Until discontinued, Starting S
Temperature less than: Systolic BP greater than: Systolic BP less than: Diastolic BP greater than: Diastolic BP less than: MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Systolic BP greater than: Systolic BP less than: Diastolic BP greater than: Diastolic BP less than: MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Systolic BP less than: Diastolic BP greater than: Diastolic BP less than: MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Diastolic BP greater than: Diastolic BP less than: MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Diastolic BP less than: MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
MAP less than: Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Heart rate greater than (BPM): Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Heart rate less than (BPM): Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
Respiratory rate greater than: Respiratory rate less than: 12 SpO2 less than: 94
SpO2 less than: 94

Routine. Until discontinued. Starting S
BUN greater than:
Creatinine greater than:
Glucose greater than:
Glucose less than:
Hct less than:
Hgb less than:
LDL greater than:
Magnesium greater than (mg/dL): 7
Magnesium less than (mg/dL): 4
Platelets less than:
Potassium greater than (mEq/L):
Potassium less than (mEq/L):
PT/INR greater than:
PT/INR less than:
PTT greater than:
PTT less than:
Serum Osmolality greater than:
Serum Osmolality less than:
Sodium greater than:
Sodium less than:
WBC greater than:
WBC less than:
Other Lab (Specify):
Routine, Until discontinued, Starting S, L&D Pre-Delivery
,
75 mL/hr, intravenous, continuous
"Followed by" Linked Panel
avenous, for 30 Minutes, once, For 1 Doses
g Dose - Bolus from Bag
nous, continuous, Starting H+30 Minutes
"Followed by" Linked Panel
avenous, for 30 Minutes, once, For 1 Doses
g Dose - Bolus from Bag
nous, continuous, Starting H+30 Minutes
ו

Rescue Agents

[X] calcium gluconate injection	1 g, intravenous, once PRN, rescue agent Administer for respirations less than 12 breaths per minute and call MD. Calcium GLUCONATE 1 gm = 4.65 MEQ
PRN Medications	
[X] PRN Antipyretics	
[X] acetaminophen (TYLENOL) tablet	oral, every 6 hours PRN, fever, for temperature GREATER than 100.4, L&D Pre-Delivery
[X] PRN Gastrointestinal Care	
[] sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet	1 tablet, oral, nightly PRN, constipation, L&D Pre-Delivery
[] docusate sodium (COLACE) capsule	100 mg, oral, 2 times daily PRN, constipation, L&D Pre-Delivery
[] alum-mag hydroxide-simeth (MAALOX MAX) 400-400-40 mg/5 mL suspension	30 mL, oral, every 3 hours PRN, indigestion, L&D Pre-Delivery
[X] Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral (Selection F	• •
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting, L&D Pre-Delivery Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, L&D Pre-Delivery
	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) IV or Oral or Re	ctal "Or" Linked Panel
[] promethazine (PHENERGAN) 12.5 mg IV	12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, L&D Pre-Delivery
	Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting, L&D Pre-Delivery Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, L&D Pre-Delivery Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
[] PRN Antihypertensives	
[] For blood pressure GREATER than or EQUAL to 160mmHg - labetalol (NORMODYNE) tablet	200 mg, oral, 2 times daily PRN, high blood pressure, L&D Pre-Delivery For Systolic blood pressure GREATER than or EQUAL to 160mmHg. DO NOT give incremental dosing as this will compromise fetal circulation. HOLD parameters for this order: Contact Physician if: Systolic BP GREATER than 160mmHg and Diastolic BP GREATER than 110 mmHg
[] hydrALAZINE (APRESOLINE) tablet	5 mg, oral, every 6 hours PRN, high blood pressure, L&D Pre-Delivery For blood pressure GREATER than 160 mmHg. DO NOT give incremental dosing as this will compromise fetal circulation. HOLD parameters for this order: Contact Physician if:
[] PRN Severe Hypertension (Single Response)	
() NIFEdipine (PROCARDIA) capsule	10 mg, oral, once PRN, high blood pressure, for severe BP elevations of 15 min or more. Recheck BP in 15 min., L&D Pre-Delivery HOLD parameters for this order: Contact Physician if: Systolic BP GREATER than 160 mmHg or Diastolic BP GREATER than 110 mmHg.
() labetalol (NORMODYNE,TRANDATE) injection	20 mg, intravenous, once PRN, high blood pressure, for severe blood pressure elevation (Systolic BP GREATER than or EQUAL to 160 mmHg) persisting for 15 minutes or more., For 1 Doses, L&D Pre-Delivery Give IV Push over 2 minutes. Repeat BP measurements in 10 minutes and record results. Contact Physician if: For Systolic BP GREATER than 160 mmHg or Diastolic BP GREAER than 110mmHg.

() hydrALAZINE (APRESOLINE) injection	10 mg, intravenous, once PRN, high blood pressure, over more than 2 minutes for severe BP elevations of 15 minutes or more. Recheck BP in 20 minutes., L&D Pre-Delivery HOLD parameters for this order: Contact Physician if: Systolic BP GREATR than 160 mmHg or Diastolic BP GREATER than 110 mmHg.
[X] Insomnia	
[X] zolpidem (AMBIEN) tablet	5 mg, oral, nightly PRN, sleep, L&D Pre-Delivery
[X] Zoipidom (AMBIEN) tablet	o mg, oral, mgmay i ma, sloop, eab i to bolivery
\/TC	
VTE	
DVT Risk and Prophylaxis Tool (Single Response	e) (Selection Required) URL: "\appt1.pdf"
() Patient currently has an active order for therapeu anticoagulant or VTE prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() LOW Risk of DVT (Selection Required)	
Low Risk Definition Age less than 60 years and NO other VTE risk fa	ctors
[] Low Risk (Single Response) (Selection Requir	red)
() Low risk of VTE	Routine, Once
() LOW HISK OF VIL	Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae
	early ambulation
() MODERATE Disk of DVT. Surgical (Salastian D	
 MODERATE Risk of DVT - Surgical (Selection Remoderate Risk Definition 	equiled)
contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflams stroke, rheumatologic disease, sickle cell disease Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hou Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	Mechanical prophylaxis is optional unless pharmacologic is mation, dehydration, varicose veins, cancer, sepsis, obesity, previous e, leg swelling, ulcers, venous stasis and nephrotic syndrome
[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Patient (Single Response) (Selection Required	
() Contraindications exist for pharmacologic pro	
BUT order Sequential compression device	
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Place/Maintain sequential compression device continuous	Routine, Continuous
Contraindications exist for pharmacologic pro AND mechanical prophylaxis	phylaxis "And" Linked Panel
	Pautino Onco
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Contraindications exist for mechanical	Routine, Once
[] Contraindications exist for mechanical prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s):

() enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () patients with CrCL LESS than 30 mL/min () patients weight between 100-139 kg AND 30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1
() enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () patients with CrCL LESS than 30 mL/min 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients with CrCL LESS than 30 mL/min 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
- · · · · · · · · · · · · · · · · · · ·
CrCl GREATER than 30 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min 40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medicatio Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet oral, daily at 1700, Starting S+1 Indication:
() Pharmacy consult to manage warfarin STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Selection Required)
() Contraindications exist for mechanical prophylaxis No mechanical VTE prophylaxis due to the following contraindication(s)
() Place/Maintain sequential compression Routine, Continuous device continuous
() MODERATE Risk of DVT - Non-Surgical (Selection Required)
Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission
[] Moderate Risk (Selection Required)
[] Moderate risk of VTE Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selection Required)
() Contraindications exist for pharmacologic prophylaxis - "And" Linked Panel Order Sequential compression device
[] Contraindications exist for pharmacologic prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s):

Routine, Continuous

[] Place/Maintain sequential compression device continuous

Contraindications exist for pharmacologic prop AND mechanical prophylaxis	ohylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Respondent (Selection Required)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, every 12 hours at 0900, 2100, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
() HIGH Risk of DVT - Surgical (Selection Required) Address both pharmacologic and mechanical prop	ohylaxis by ordering from Pharmacological and Mechanical Prophylaxis.
[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgion (Single Response) (Selection Required)	
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):

<u> </u>	honorin (norcino) injection	5 000 Units, subsultaneous, every 8 hours, S+1 at, 6:00 AM
()	heparin (porcine) injection heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
()	for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1
	· · · · · · · · · · · · · · · · · · ·	Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
	GH Risk of DVT - Non-Surgical (Selection Requir	
Add	dress both pharmacologic and mechanical proph	ylaxis by ordering from Pharmacological and Mechanical Prophylaxis.
[]	High Risk (Selection Required)	
' <u> </u>	High risk of VTE	Routine, Once
	High Risk Pharmacological Prophylaxis - Non-Su	
<u> </u>	Patient (Single Response) (Selection Required)	
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	enoxaparin (LOVENOX) injection (Single Respo	
-	(Selection Required)	<u> </u>
	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily, Starting S+1
	patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily, Starting S+1 For Patients with CrCL LESS than 30 mL/min
()	patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
$\overline{()}$	patients weight 140 kg or GREATER AND	40 mg, subcutaneous, every 12 hours at 0900, 2100
	CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
		If the patient does not have a history of or suspected case of
		Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive
		procedure, or CrCl LESS than 30 mL/min.
		This patient has a history of or suspected case of Heparin-Induced
		Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g.	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS
	weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700
.,	,	Indication:
()	Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
/ \	(COUMADIN)	Indication:
` '	GH Risk of DVT - Surgical (Hip/Knee) (Selection quired)	
		ylaxis by ordering from Pharmacological and Mechanical Prophylaxis.
F 1 .	limb Dialy (Calastian Daminad)	
[] [High Risk (Selection Required) High risk of VTE	Routine, Once
[]	High Risk Pharmacological Prophylaxis - Hip or F	
(Arthroplasty) Surgical Patient (Single Response Selection Required)	
()	Contraindications exist for pharmacologic	Routine, Once
	prophylaxis	No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	apixaban (ELIQUIS) tablet	contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1
()	apmasan (EEIQOIO) tasiot	Indications:
()	aspirin chewable tablet	162 mg, oral, daily, Starting S+1
()	aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
()	enoxaparin (LOVENOX) injection (Single Responsable (Selection Required)	onse)

<u></u>	(1.0)(ENOV)	40
()	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
()	enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min.
()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
()	enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medicatio Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1 To be Given on Post Op Day 1. Indications:
()	warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1 Indication:
	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
VT Ris	sk and Prophylaxis Tool (Single Response)	URL: "\appt1.pdf"
	ent currently has an active order for therapeutic coagulant or VTE prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
) LOV	V Risk of DVT (Selection Required)	
<u> </u>	Risk Definition	
	less than 60 years and NO other VTE risk factor	ors
[] L	ow Risk (Single Response) (Selection Required	(I)
	Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourged early ambulation
) MO	DERATE Risk of DVT - Surgical (Selection Req	uired)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once
 [] Moderate Risk Pharmacological Prophylaxis - S Patient (Single Response) (Selection Required) 	
() Contraindications exist for pharmacologic prop BUT order Sequential compression device	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Place/Maintain sequential compression device continuous	Routine, Continuous
Contraindications exist for pharmacologic prop AND mechanical prophylaxis	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 3 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

() MODERATE Risk of DVT - Non-Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[1] Moderate Diek (Colection Dequired)	
[] Moderate Risk (Selection Required) [] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selec Required)	
() Contraindications exist for pharmacologic prop Order Sequential compression device	phylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Place/Maintain sequential compression device continuous	Routine, Continuous
Contraindications exist for pharmacologic propagation AND mechanical prophylaxis	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:

STAT, Until discontinued, Starting S () Pharmacy consult to manage warfarin (COUMADIN) Indication:

HIGH Risk of DVT - Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required)		
[] High risk of VTE	Routine, Once	
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) (Selection Required)		
() Contraindications exist for pharmacologic	Routine, Once	
prophylaxis	No pharmacologic VTE prophylaxis due to the following contraindication(s):	
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1	
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min	
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):	
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM	
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.	
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1 Indication:	
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:	
[] Mechanical Prophylaxis (Single Response) (Se Required)	lection	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):	
() Place/Maintain sequential compression device continuous	Routine, Continuous	

() HIGH Risk of DVT - Non-Surgical (Selection Required)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High risk of VTE	Routine, Once
 High Risk Pharmacological Prophylaxis - Non-St Patient (Single Response) (Selection Required) 	urgical
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 3 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Mechanical Prophylaxis (Single Response) (Sele Required)	ection
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s
() Place/Maintain sequential compression device continuous	Routine, Continuous

Required)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

] High risk of VTE	Routine, Once
High Risk Pharmacological Prophylaxis - Hip or (Arthroplasty) Surgical Patient (Single Respons (Selection Required)	Knee
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
() enoxaparin (LOVENOX) syringe - For	30 mg, subcutaneous, daily at 0600, Starting S+1
Patients with CrCL LESS than 30 mL/min	For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL)
Patients weight between 100-139 kg and	Starting S+1
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 3 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 3 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or	10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1
knee arthroplasty planned during this	To be Given on Post Op Day 1.
admission	Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Mechanical Prophylaxis (Single Response) (Se Required)	lection
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s

		-	
	() Place/Maintain sequential compression device continuous	Routine,	Continuous
DV	T Risk and Prophylaxis Tool (Single Response) (Selectio	n Required) URL: "\appt1.pdf"
` '	Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis	-	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
	LOW Risk of DVT (Selection Required)		
	Low Risk Definition Age less than 60 years and NO other VTE risk factor	ors	
<u> </u>	Low Risk (Single Response) (Selection Required)	
	() Low risk of VTE	Routine, Low risk early am	: Due to low risk, no VTE prophylaxis is needed. Will encourgae
	MODERATE Risk of DVT - Surgical (Selection Requipment Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Me contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflamma stroke, rheumatologic disease, sickle cell disease, leage 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	chanical ition, deh eg swellir	ydration, varicose veins, cancer, sepsis, obesity, previous
[Moderate Risk (Selection Required)		
-	Moderate risk of VTE	Routine,	Once
l	 Moderate Risk Pharmacological Prophylaxis - Su Patient (Single Response) (Selection Required) 	irgicai	
	() Contraindications exist for pharmacologic proph BUT order Sequential compression device	ıylaxis	"And" Linked Panel
	[] Contraindications exist for pharmacologic prophylaxis	No pha contrai	e, Once rmacologic VTE prophylaxis due to the following ndication(s):
	[] Place/Maintain sequential compression device continuous		e, Continuous
	Contraindications exist for pharmacologic proph AND mechanical prophylaxis		"And" Linked Panel
	[] Contraindications exist for pharmacologic prophylaxis	No pha	e, Once rmacologic VTE prophylaxis due to the following ndication(s):
	[] Contraindications exist for mechanical prophylaxis	No med	e, Once chanical VTE prophylaxis due to the following ndication(s):
	() enoxaparin (LOVENOX) injection (Single Responsable (Selection Required)	onse)	
	() enoxaparin (LOVENOX) syringe		subcutaneous, daily at 0600, Starting S+1
	() patients with CrCL LESS than 30 mL/min		subcutaneous, daily at 0600, Starting S+1 tients with CrCL LESS than 30 mL/min
	() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min		subcutaneous, 2 times daily at 0600, 1800, Starting S+1 tients weight between 100-139 kg and CrCl GREATER than 30

	() patients weight 140 kg or GREATER AN CrCl GREATER than 30 mL/min	Starting S+1
		For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
	() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
		If the patient does not have a history of or suspected case of
		Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication.
		Contraindicated in patients LESS than 50kg, prior to surgery/invasive
		procedure, or CrCl LESS than 30 mL/min.
		This patient has a history of or suspected case of Heparin-Induced
		Thrombocytopenia (HIT):
	() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
	() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
	for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LESS
	weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
	() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1
		Indication:
	() Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
	(COUMADIN)	Indication:
7)	MODERATE Risk of DVT - Non-Surgical (Sele	ection

() MODERATE Risk of DVT - Non-Surgical (Selection

Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once
 Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selecti Required) 	ion
() Contraindications exist for pharmacologic prop Order Sequential compression device	hylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Place/Maintain sequential compression device continuous	Routine, Continuous
() Contraindications exist for pharmacologic prop AND mechanical prophylaxis	hylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	onse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S

() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
) HI	GH Risk of DVT - Surgical (Selection Required)	

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

II High Dista (Octor flow Demoiss I)		
[] High Risk (Selection Required)	Double Occur	
[] High risk of VTE	Routine, Once	
[] High Risk Pharmacological Prophylaxis - Surgi (Single Response) (Selection Required)	cal Patient	
() Contraindications exist for pharmacologic	Routine, Once	
prophylaxis	No pharmacologic VTE prophylaxis due to the following	
	contraindication(s):	
() enoxaparin (LOVENOX) injection (Single Response) (Selection Required)		
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1	
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1	
., .	For Patients with CrCL LESS than 30 mL/min	
() patients weight between 100-139 kg AND	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1	
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30	
	mL/min	
() patients weight 140 kg or GREATER AND	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1	
CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1	
	If the patient does not have a history or suspected case of	
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication.	
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive	
	procedure, or CrCl LESS than 30 mL/min.	
	This patient has a history of or suspected case of Heparin-Induced	
	Thrombocytopenia (HIT):	
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM	

() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1
	Indication:
() Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
(COUMADIN)	Indication:
] Mechanical Prophylaxis (Single Response) (Se	lection
Required)	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression	Routine, Continuous
device continuous	
HIGH Risk of DVT - Non-Surgical (Selection Requ	ired)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	Deuting Ones
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Non-S Patient (Single Response) (Selection Required)	
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

Mechanical Prophylaxis (Single Response) (Selection Required)

()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
()		Routine, Continuous
\	OLL District DVT Commission (Ulis //Commission)	

() HIGH Risk of DVT - Surgical (Hip/Knee) (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required) [] High risk of VTE	Routine, Once
High Risk Pharmacological Prophylaxis - Hip of (Arthroplasty) Surgical Patient (Single Respon- (Selection Required)	r Knee
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	sponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
 enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCl GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medicatio Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1 Indication:

() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Required)	Selection
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s
() Place/Maintain sequential compression device continuous	Routine, Continuous
abs Today	
abs HMH	
Rubella antibody, IgG	Once, L&D Pre-Delivery
Surgical pathology request	Collection Date: 9/17/2020
1 Cargical painteregy request	Collection Time:
	Surgical Specimen:
	Gestational Age:
	Specimen Site:
	Number of specimens:
	Malignancy:
	Irradiation:
	Specimen Status:
	Chemotherapy:
	Hormonal Therapy: Clinical History:
	Pre-Operative Diagnosis:
	Procedure Type:
	L&D Pre-Delivery
Urine drugs of abuse screen	Once, L&D Pre-Delivery
K] OB Panel	
[X] CBC with differential	Once, L&D Pre-Delivery
Basic metabolic panel	Once, L&D Pre-Delivery
[X] Hepatitis B surface antigen	Once, L&D Pre-Delivery
[X] HIV Ag/Ab combination	Once, L&D Pre-Delivery
[X] Syphilis total antibody	Once, L&D Pre-Delivery
[X] Type and Screen, Obstetrical Patient	Once, L&D Pre-Delivery
[] Urine dipstick	Once, L&D Pre-Delivery
[X] Urinalysis screen and microscopy, with	Once
reflex to culture	Specimen Source: Urine
	Specimen Site: L&D Pre-Delivery
Pre-Eclamptic Lab Panel	Lad Fre-Delivery
BC with differential	Once, L&D Pre-Delivery
[] Comprehensive metabolic panel	Once, L&D Pre-Delivery
[] Prothrombin time with INR	Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Uric acid	Once, L&D Pre-Delivery
[] LDH	Once, L&D Pre-Delivery
[] Urine Protein and Creatinine	
[] Creatinine level, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Protein, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
] Fetal Demise Panel	
[] Antibody screen (gel)	Once
[] Antithrombin III level	Once, L&D Pre-Delivery
[] Cardiolipin antibodies	Once, L&D Pre-Delivery
[] Factor V leiden by PCR	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
	Once
Hemoglobin A1c	Office
[] Hemoglobin A1c [] Homocystine, plasma	Once, L&D Pre-Delivery

[1] Lunus entiresegulant panel	Once L & D. Dro Delivery
[] Lupus anticoagulant panel	Once, L&D Pre-Delivery
[] Parvovirus B19 antibody, IgG and IgM	Once, L&D Pre-Delivery
[] Prothrombin mutation, factor II, by PCR	Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery
[] Prothrombin time with INR	Once, L&D Pre-Delivery
[] TSH	Once, L&D Pre-Delivery
Labs HMW, HMSL	
[] Blood gas, arterial, cord	Once, L&D Pre-Delivery
[] Blood gas, venous, cord	Once, L&D Pre-Delivery
[] Rubella antibody, IgG	Once, L&D Pre-Delivery
[] Surgical pathology request	Collection Date: 9/17/2020
	Collection Time:
	Surgical Specimen:
	Gestational Age:
	Specimen Site:
	Number of specimens:
	Malignancy:
	Irradiation:
	Specimen Status:
	Chemotherapy: Hormonal Therapy:
	Clinical History:
	Pre-Operative Diagnosis:
	Procedure Type:
	L&D Pre-Delivery
[] Urine drugs of abuse screen	Once, L&D Pre-Delivery
[] Bedside glucose	Routine, Once, L&D Pre-Delivery
[] OB Panel	reduite, ones, Edd rife Belliery
[] Bedside glucose	Routine, Every hour, L&D Pre-Delivery
[] CBC with differential	Once, L&D Pre-Delivery
[] Basic metabolic panel	Once, L&D Pre-Delivery
[] Hepatitis B surface antigen	Once, L&D Pre-Delivery
[] Rapid HIV 1 & 2	Once, L&D Pre-Delivery
[] Syphilis total antibody	Once, L&D Pre-Delivery
[] Type and Screen, Obstetrical Patient	Once, L&D Pre-Delivery
[] Urinalysis screen and microscopy, with	Once
reflex to culture	Specimen Source: Urine
Tollox to culture	Specimen Site:
	L&D Pre-Delivery
Pre-Eclamptic Lab Panel	<u> </u>
[] CBC with differential	Once, L&D Pre-Delivery
[] Comprehensive metabolic panel	Once, L&D Pre-Delivery
Prothrombin time with INR	Once, L&D Pre-Delivery
Partial thromboplastin time	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Uric acid	Once, L&D Pre-Delivery
[] LDH	Once, L&D Pre-Delivery
Urine Protein and Creatinine	
[] Creatinine level, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
Protein, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Fetal Demise Panel	2
[] Antibody screen (gel)	Once
[] Antithrombin III level	Once, L&D Pre-Delivery
[] Cardiolipin antibodies	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Factor V leiden by PCR	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Hemoglobin A1c	Once
[] Homocystine, plasma	Once, L&D Pre-Delivery
[] Kleihauer-Betke	•
[] Vieillanei-Derke	Once

	0 L0DD D I
[] Lupus anticoagulant panel	Once, L&D Pre-Delivery
[] Parvovirus B19 antibody, IgG and IgM	Once, L&D Pre-Delivery
[] Prothrombin mutation, factor II, by PCR [] Partial thromboplastin time	Once, L&D Pre-Delivery
11 	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
	Once, L&D Pre-Delivery
[] TSH	Office, Lad Fre-Delivery
Labs HMSJ	
[] Cord blood gas, arterial	STAT For 1 Occurrences, L&D Pre-Delivery
[] Cord blood gas, venous	STAT For 1 Occurrences, L&D Pre-Delivery
[] Rubella antibody, lgG	Once, L&D Pre-Delivery
[] Surgical pathology request	Collection Date: 9/17/2020
	Collection Time:
	Surgical Specimen:
	Gestational Age:
	Specimen Site: Number of specimens:
	Malignancy:
	Irradiation:
	Specimen Status:
	Chemotherapy:
	Hormonal Therapy:
	Clinical History:
	Pre-Operative Diagnosis:
	Procedure Type:
	L&D Pre-Delivery
Urine drugs of abuse screen	STAT For 1 Occurrences, L&D Pre-Delivery
[] Bedside glucose [X] OB Panel	Routine, Once, L&D Pre-Delivery
[X] OB Panel [X] CBC with differential	STAT For 1 Occurrences 1 2D Pro Dolivony
[] Basic metabolic panel	STAT For 1 Occurrences, L&D Pre-Delivery STAT For 1 Occurrences, L&D Pre-Delivery
[X] Hepatitis B surface antigen	STAT For 1 Occurrences, L&D Pre-Delivery STAT For 1 Occurrences, L&D Pre-Delivery
[] HIV 1, 2 antibody	Once, L&D Pre-Delivery
[X] Syphilis total antibody	Once, L&D Labs
[X] Type and Screen, Obstetrical Patient	STAT For 1 Occurrences, L&D Pre-Delivery
[X] Urinalysis screen and microscopy, with	STAT For 1 Occurrences
reflex to culture	Specimen Source: Urine
	Specimen Site:
	L&D Pre-Delivery
Pre-Eclamptic Lab Panel	Once LAD Des Dell's cons
[] CBC with differential	Once, L&D Pre-Delivery
[] Comprehensive metabolic panel	Once, L&D Pre-Delivery
Prothrombin time with INR	Once, L&D Pre-Delivery
Partial thromboplastin time	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Uric acid	Once, L&D Pre-Delivery
LDH LI Uring Protoin and Creatining	Once, L&D Pre-Delivery
Urine Protein and Creatinine Creatining level uring random	Once For 1 Occurrences 1 2D Drs Delivery
[] Creatinine level, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Protein, urine, random [] Fetal Demise Panel	Once For 1 Occurrences, L&D Pre-Delivery
[] Fetal Demise Panel [] Antibody screen (gel)	Once
	STAT For 1 Occurrences, L&D Pre-Delivery
11	Once, L&D Pre-Delivery
	STAT For 1 Occurrences, L&D Pre-Delivery
[] Factor V leiden by PCR [] Fibrinogen	STAT For 1 Occurrences, L&D Pre-Delivery STAT For 1 Occurrences, L&D Pre-Delivery
[] Hemoglobin A1c	Once
[] Homocystine, plasma	STAT For 1 Occurrences, L&D Pre-Delivery
[] Homocystine, plasma [] Kleihauer-Betke	Once
	STAT For 1 Occurrences, L&D Pre-Delivery
[] Lupus anticoagulant panel	STAT FOL TOCCUTTETICES, LAD PTE-DETIVETY

Parvovirus B19 antibody, IgG and IgM	STAT For 1 Occurrences, L&D Pre-Delivery
[STAT For 1 Occurrences, L&D Pre-Delivery
Prothrombin mutation, factor II, by PCR Partial thromboplastin time	STAT For 1 Occurrences, L&D Pre-Delivery
[] Prothrombin time with INR	· · · · · · · · · · · · · · · · · · ·
	STAT For 1 Occurrences, L&D Pre-Delivery
[] TSH	STAT For 1 Occurrences, L&D Pre-Delivery
Labs - HMSTJ	
[] Blood gas, arterial, cord	Once, L&D Pre-Delivery
[] Blood gas, venous, cord	Once, L&D Pre-Delivery
[] Rubella antibody, IgG	Once, L&D Pre-Delivery
[] Surgical pathology request	Collection Date: 9/17/2020
	Collection Time:
	Surgical Specimen:
	Gestational Age:
	Specimen Site:
	Number of specimens:
	Malignancy:
	Irradiation: Specimen Status:
	Chemotherapy:
	Hormonal Therapy:
	Clinical History:
	Pre-Operative Diagnosis:
	Procedure Type:
	L&D Pre-Delivery
[] Urine drugs of abuse screen	Once, L&D Pre-Delivery
[X] OB Panel	<u> </u>
Instead of using LAB4120, this order panel use	s LAB276.
[] CBC with platelet and differential	Once, L&D Pre-Delivery
[] Basic metabolic panel	Once, L&D Pre-Delivery
[] HIV 1, 2 antibody	Once, L&D Pre-Delivery
[] Hepatitis B surface antigen	Once, L&D Pre-Delivery
[] Syphilis treponema screen with RPR	Once, L&D Pre-Delivery
confirmation (reverse algorithm)	
[] Type and screen	Once, L&D Pre-Delivery
[] Urinalysis, dipstick only	Once, L&D Pre-Delivery
[] Urinalysis screen and microscopy, with	Once
reflex to culture	Specimen Source: Urine
	Specimen Site:
II. Bu Edwarf Lab Band	L&D Pre-Delivery
[] Pre-Eclamptic Lab Panel	Once L 9D Dre Delivery
[] CBC with differential [] Comprehensive metabolic panel	Once, L&D Pre-Delivery
[] Prothrombin time with INR	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Uric acid	Once, L&D Pre-Delivery
[] LDH	Once, L&D Pre-Delivery
[] Urine Protein and Creatinine	Silos, East 10 Solitory
[] Creatinine level, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Protein, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Fetal Demise Panel	
[] Antibody screen (gel)	Once
[] Antithrombin III level	Once, L&D Pre-Delivery
[] Cardiolipin antibodies	Once, L&D Pre-Delivery
[] Factor V leiden by PCR	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Hemoglobin A1c	Once
[] Homocystine, plasma	Once, L&D Pre-Delivery

[] Kleihauer-Betke	Once
[] Lupus anticoagulant panel	Once, L&D Pre-Delivery
[] Parvovirus B19 antibody, IgG and IgM	Once, L&D Pre-Delivery
[] Prothrombin mutation, factor II, by PCR	.
	Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery
<u></u> ——————————————————————————————————	Once, L&D Pre-Delivery
[] TSH	Once, L&D Pre-Delivery
Labs HMTW	
Blood gas, arterial, cord	Once, L&D Pre-Delivery
[] Blood gas, venous, cord	Once, L&D Pre-Delivery
[] Rubella antibody, IgG	Once, L&D Pre-Delivery
Surgical pathology request	Collection Date: 9/17/2020
	Collection Time:
	Surgical Specimen:
	Gestational Age:
	Specimen Site:
	Number of specimens:
	Malignancy:
	Irradiation:
	Specimen Status:
	Chemotherapy:
	Hormonal Therapy:
	Clinical History:
	Pre-Operative Diagnosis:
	Procedure Type:
[1] This days of the control	L&D Pre-Delivery
[] Urine drugs of abuse screen	Once, L&D Pre-Delivery
[X] OB Panel	On and I OD Dura Deliverers
[X] CBC with differential	Once, L&D Pre-Delivery
Basic metabolic panel	Once, L&D Pre-Delivery
[X] Hepatitis B surface antigen	Once, L&D Pre-Delivery
[] HIV 1, 2 antibody	Once, L&D Pre-Delivery
[X] Syphilis total antibody	Once, L&D Pre-Delivery
[X] Type and Screen, Obstetrical Patient	Once, L&D Pre-Delivery
[X] Urinalysis screen and microscopy, with	Once
reflex to culture	Specimen Source: Urine
	Specimen Site:
II Des Calamentia Lab Daniel	L&D Pre-Delivery
[] Pre-Eclamptic Lab Panel	Once I 9D Dre Delivery
[] CBC with differential	Once, L&D Pre-Delivery
[] Comprehensive metabolic panel	Once, L&D Pre-Delivery
[] Prothrombin time with INR	Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Uric acid	Once, L&D Pre-Delivery
[] LDH	Once, L&D Pre-Delivery
[] Urine Protein and Creatinine	
[] Creatinine level, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Protein, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Fetal Demise Panel	
[] Antibody screen (gel)	Once
[] Antithrombin III level	Once, L&D Pre-Delivery
[] Cardiolipin antibodies	Once, L&D Pre-Delivery
[] Factor V leiden by PCR	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Hemoglobin A1c	Once
[] Homocystine, plasma	Once, L&D Pre-Delivery
[] Kleihauer-Betke	Once
[] Lupus anticoagulant panel	Once, L&D Pre-Delivery
11 L1 Zapas anasougulain panoi	55, 265 . 15 5 65,

[] Parvovirus B19 antibody, IgG and IgM	Once, L&D Pre-Delivery
[] Prothrombin mutation, factor II, by PCR	Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery
Prothrombin time with INR	Once, L&D Pre-Delivery
[] TSH	Once, L&D Pre-Delivery
Labs HMWB	
[] Rubella antibody, IgG	Once, L&D Pre-Delivery
[] Surgical pathology request	Collection Date: 9/17/2020
	Collection Time:
	Surgical Specimen:
	Gestational Age:
	Specimen Site: Number of specimens:
	Malignancy:
	Irradiation:
	Specimen Status:
	Chemotherapy:
	Hormonal Therapy:
	Clinical History:
	Pre-Operative Diagnosis:
	Procedure Type:
[] Urine drugs of abuse serson	L&D Pre-Delivery Once, L&D Pre-Delivery
[] Urine drugs of abuse screen [] Bedside glucose	Routine, Once, L&D Pre-Delivery
[X] OB Panel	Roduine, Once, Ead Fie-Delivery
[] CBC with platelet and differential	Once For 1 Occurrences, L&D Pre-Delivery
Basic metabolic panel	Once For 1 Occurrences, L&D Pre-Delivery
[] HIV 1, 2 antibody	Once For 1 Occurrences, L&D Pre-Delivery
[] Hepatitis B surface antigen	Once For 1 Occurrences, L&D Pre-Delivery
[] Syphilis treponema screen with RPR	Once For 1 Occurrences, L&D Pre-Delivery
confirmation (reverse algorithm)	<u> </u>
[] Type and screen, obstetrical patient	Once For 1 Occurrences, L&D Pre-Delivery
[] Urinalysis, dipstick only	Once For 1 Occurrences, L&D Pre-Delivery
[] Urinalysis screen and microscopy, with	Once For 1 Occurrences
reflex to culture	Specimen Source: Urine
	Specimen Site: L&D Pre-Delivery
Pre-Eclamptic Lab Panel	L&D F1e-Delivery
[] CBC with differential	Once, L&D Pre-Delivery
[] Comprehensive metabolic panel	Once, L&D Pre-Delivery
Prothrombin time with INR	Once, L&D Pre-Delivery
[] Partial thromboplastin time	Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery
[] Uric acid	Once, L&D Pre-Delivery
[] LDH	Once, L&D Pre-Delivery
[] Urine Protein and Creatinine	
[] Creatinine level, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Protein, urine, random	Once For 1 Occurrences, L&D Pre-Delivery
[] Fetal Demise Panel	Ones
[] Antibody screen (gel) [] Antithrombin III level	Once L&D Pre Delivery
[] Cardiolipin antibodies	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Factor V leiden by PCR	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Fibrinogen	Once, L&D Pre-Delivery Once, L&D Pre-Delivery
[] Hemoglobin A1c	Once, L&D Pre-Delivery
[] Homocystine, plasma	Once, L&D Pre-Delivery
[] Kleihauer-Betke	Once
[] Lupus anticoagulant panel	Once, L&D Pre-Delivery
[] Parvovirus B19 antibody. IgG and IgM	Once, L&D Pre-Delivery

Once, L&D Pre-Delivery

[] Parvovirus B19 antibody, IgG and IgM

[] Prothrombin mutation, factor II, by PCR One	ce, L&D Pre-Delivery
[] Partial thromboplastin time One	ce, L&D Pre-Delivery
	ce, L&D Pre-Delivery
[] TSH One	ce, L&D Pre-Delivery
Chemistry	
[] Basic metabolic panel	Once
[] Comprehensive metabolic panel	Once
[] Fetal fibronectin	Once
[] Hepatic function panel	Once
[] Magnesium	Once
Chemistry	
[] Basic metabolic panel	Once
[] Comprehensive metabolic panel	Once
[] Fetal fibronectin	Once
[] Hepatic function panel	Once
[] OB magnesium level	Once
Microbiology	
[] Urinalysis screen and microscopy, with reflex to culture	
	Specimen Source: Urine
	Specimen Site:
Beta Strep Screen Culture with Lim Broth	Once, Vaginal
[] Neisseria gonorrhoeae by PCR	Once
	Urine is the only acceptable source for patients less than or
	equal to 13 years old. Specimen source: Urine
	Specimen Source:
[1] Chlamavdia trachamatia hy DCD	Specimen Site:
[] Chlamydia trachomatis by PCR	Once Urine is the only acceptable source for patients less than or
	equal to 13 years old. Specimen source: Urine
	Specimen Source:
	Specimen Site:
24 Hour Urine	
[] 24 Hour urine	
[] Creatinine clearance, urine, 24 hour One	ce, Starting S+1
[] Protein, urine, 24 hour One	ce, Starting S+1
Labs Tomorrow	
Chemistry	
[] Comprehensive metabolic panel	Once, Starting S+1
[] Electrolyte panel	Conditional Frequency For 1 Occurrences
[1 = 2.000.01) to parior	Electrolyte panel after 24 hours if receiving combination of
	Pitocin and Magnesium Sulfate therapy
[] Magnesium	Once, Starting S+1
Chemistry	
[] Comprehensive metabolic panel	Once, Starting S+1
[] OB magnesium level	Once
[] Electrolyte panel	Conditional Frequency For 1 Occurrences
	Electrolyte panel after 24 hours if receiving combination of
	Pitocin and Magnesium Sulfate therapy

Consults
For Physician Consult orders use sidebar

[] Consult to Case Management	Consult Reason:
[] Consult to Nutrition Services	Reason For Consult?
	Purpose/Topic:
[] Consult PT eval and treat	Reasons for referral to Physical Therapy (mark all applicable)
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation(if
	values are very abnormal):
	Weight Bearing Status:
[] Consult to Social Work	Reason for Consult:
[] Consult to Spiritual Care	Reason for consult?
[] Consult to Respiratory Therapy	Reason for Consult?
Physician Consults	
[] Consult Anesthesiology	Reason for Consult?
57	Patient/Clinical information communicated?
	Patient/clinical information communicated?
	Patient/clinical information communicated? L&D Pre-Delivery
Onsult Maternal and Fetal Medicine	
[] Consult Maternal and Fetal Medicine	L&D Pre-Delivery
[] Consult Maternal and Fetal Medicine	L&D Pre-Delivery Reason for Consult?
Consult Maternal and Fetal Medicine	L&D Pre-Delivery Reason for Consult? Patient/Clinical information communicated?
	L&D Pre-Delivery Reason for Consult? Patient/Clinical information communicated? Patient/clinical information communicated?
•	L&D Pre-Delivery Reason for Consult? Patient/Clinical information communicated? Patient/clinical information communicated? L&D Pre-Delivery
	L&D Pre-Delivery Reason for Consult? Patient/Clinical information communicated? Patient/clinical information communicated? L&D Pre-Delivery Reason for Consult?